RUNX2 and cancer: Instead, we not only verified the tumorigenic role of RUNX2 in TNBC progression and cancer chemoresistance both in vitro and in vivo, but also revealed the regulatory mechanism of RUNX2 via directly targeting the specific binding site in the promoter region of MMP1.